Skip to content

Contact +44 (0) 20 7060 7474 email us

AIDS & HIV

HIV: A Strategic Analysis of Therapeutic and Testing Markets

 

Publication Date March 2006
Publisher Kalorama Information
Product Type Report
Pages 200
ISBN Number not applicable
Product Code KAL00079

Price

£2,310.00
approximately: $3,498 | €2,578

pdf

Buy Now

print

Buy Now

Order above formats by FAX

Order by Fax

Summary

The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions.

For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three primary areas, the first of which is strongly influenced by the latter two:

  • market potential,
  • epidemiology (including HIV/AIDS patient trends) and
  • the current and emerging technologies in both diagnostics and therapeutics.

This in-depth strategic analysis of the worldwide HIV/AIDS market discusses the technologies available and emerging and discusses realistic and theoretical market potential and detailed epidimiological assessments for various geographic regions (many to the national level), including:

  • Sub-Saharan Africa
  • North Africa/Middle East
  • South/Southeast Asia
  • East Asia
  • Latin America
  • Caribbean
  • Eastern Europe/Central Asia
  • Western/Central Europe
  • North America
  • Oceania

The report focuses on the policy aspects of HIV/AIDS, the options presented, the factors associated with strategic market development of HIV/AIDS diagnostics and therapeutics, and prospects for the future. The major strategic market effects of epidemiology, medical technology, and market potential analyses are discussed in detail. The trends in epidemiology and social/political attitudes towards HIV/AIDS, as well as their impacts on developing markets, are selected in conjunction with the growing interest in HIV/AIDS preventive medicine. These are presented to provide the most informative picture of potential market advances in this field.

Market analysis for this report is limited in the sense of projections, market shares, etc. Instead, it considers the various aspects of broad market development and estimates throughout the world. It looks at regions of the globe in terms of their existing theoretic and realist market potential. This is tempered by discussions of where and how these markets may develop and the factors influencing them. This report does not discuss in detail the individual products that may be marketed in each of these countries. Some mention is made of specific product types by way of example, but greater emphasis is placed on the product classes, in their generic sense, and their application to HIV/AIDS per se and its complications. The focus of the report is on the strategic factors associated with existing and future market potentials to provide pharmaceutical and diagnostics companies wishing to enter the field with a field general's perspective.

Contents

  • Chapter 1: Executive Summary
    • Market Potential
    • Epidemiology
    • Technology
      • Screening and Diagnosis
        • Level 1: Screening for HIV Infection
        • Level 2: Confirmatory Testing for HIV Infection
        • Level 3: Diagnosis
        • Level 4: Monitoring Treatment and Prognosis
      • Therapeutics
        • Binding
        • Reverse Transcription
        • Transcription
        • Translation
        • Viral Assembly and Maturation
        • Other Areas
    • Scope and Methodology
  • Chapter 2: HIV/AIDS: Nature and Epidemiology
    • HIV/AIDS Basics
    • HIV/AIDS Complications
      • Pneumocystis carinii pneumonia
      • Tuberculosis
      • Toxoplasmosis
      • Cytomegalovirus (CMV)
      • Mycobacterium avium complex
      • Kaposi's sarcoma
      • Non-Hodgkin's Lymphoma
      • Primary CNS Lymphoma
      • Hodgkin's Disease
      • Cervical Cancer
      • Anal Cancer
      • Coinfection with Hepatitis C
    • HIV/AIDS Epidemiology
    • HIV/AIDS in the United States
    • HIV/AIDS in Western Europe
    • HIV/AIDS in Central Europe, Eastern Europe and Central Asia
    • HIV/AIDS in Africa
    • HIV/AIDS in Latin America and the Caribbean
    • HIV/AIDS in India, China and South/Southeast Asia
      • India
      • China
      • South and Southeast Asia
      • HIV/AIDS in North Africa and the Middle East
  • Chapter 3: Screening and Diagnosis
    • Level 1: Screening
    • Level 2: Confirmatory Testing
    • Level 3: Diagnosis
    • Level 4: Monitoring Treatment and Prognosis
  • Chapter 4: HIV/AIDS: Therapeutics
    • Drug Therapy
      • Binding
        • AMD070 (AnorMED, Inc.)
        • BMS-488043 (Bristol-Myers Squibb)
        • GSK-873,140 [aplaviroc] (GlaxoSmithKline)
        • Peptide T (Advanced Immuni T, Inc.)
        • PRO-542 (Progenics Pharmaceuticals, Inc.)
        • SCH-C (Schering Plough Corp.)
        • SCH-D [vicriviroc] (Schering Plough Corp.)
        • TNX-355 (Tanox, Inc.)
        • UK-427,857 [maraviroc] (Pfizer Inc.)
      • Reverse Transcription
        • Alovudine (Boehringer Ingelheim GmbH)
        • Amdoxovir [DAPD] (Gilead Sciences Inc.)
        • AVX754 (Avexa Limited)
        • DPC 817 [Reverset] (Pharmasset, Inc.)
        • Elvucitabine (Achillion Pharmaceuticals)
        • KP-1461 [SN1461, SN1212, KP-1212, KP1212/1461] (Koronis Pharmaceuticals)
        • Racivir (Pharmasset, Inc.)
        • Calanolide A (Sarawak MediChem Pharmaceuticals, Inc.)
        • Capravirine (Pfizer, Inc,)
        • TMC125 (Tibotec)
      • Integration
        • L-000870810 (Merck & Co., Inc.)
        • Transcription
        • Translation
        • Viral Assembly and Maturation
    • Microbicides
      • C31G (Cellegy Pharmaceuticals, Inc.)
      • Carbopol 974P [BufferGel] (ReProtect LLC)
      • Carrageenan [Carraguard] (FMC Biopolymer; Population Council)
      • Cellulose Sulfate [Ushercell] (Polydex Pharmaceuticals Ltd.)
      • Cyanovirin-N (Cellegy Pharmaceuticals, Inc.)
      • Dextran sulfate (Ueno Fine Chemicals Industry Ltd)
      • PRO 2000 (Indevus Pharmaceuticals, Inc.)
      • UC-781 (Cellegy Pharmaceuticals, Inc.)
        • Chemokine Therapeutics
        • Genes and HIV/AIDS
        • HIV/AIDS Vaccines
    • Therapeutic Vaccines
      • Phase I - Safety/Immunogenicity of Immunizations of ALVAC-DC-SC Vs ALVAC-SC (NIAID: NCT00026624)
      • Phase II - Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients (NIAID: NCT00080106)
      • Phase III - Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy (NIAID: NCT00107549)
      • Phase I - Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART) (GlaxoSmithKline: NCT00117429)
      • Phase I/Phase II - Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection (NIAID: NCT00125099
      • Phase II - Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection (NIAID: NCT00183261)
      • Phase I/Phase II - Safety and Tolerability of and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving Anti-HIV Treatment (NIAID: NCT00270205)
    • Preventive Vaccines
      • No Phase - A Study to Prepare for Future HIV Vaccine Studies (NIAID: NCT00029744)
      • No Phase - Screening Protocol for HIV Vaccine Studies (NIAID: NCT00031304)
      • Phase I - Development of a New HIV Vaccine (NIAID: NCT00051922)
      • Phase I - Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults (NIAID: NCT 00083603)
      • Phase I - Safety of an Oral Vaccine in HIV Uninfected Volunteers (NIAID: NCT00062530)
      • Phase I - Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults (NIAID: NCT00097838)
      • Phase I - Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers (NIAID, NICHD, NIDA, NIMH: NCT00098163)
      • Phase I - Study of HIV Preventive Vaccines Given With or Without an Adjuvant in HIV Uninfected Adults (NIAID: NCT00111605)
      • Phase I - Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 3 Different Booster Vaccinations in HIV Uninfected Adults (NIAID: NCT00115960)
      • Phase I - Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults (NIAID: NCT00119873)
      • Phase I/Phase II - Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults (NIAID, DOD: NCT00123968)
      • Phase I - Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults (NIAID: NCT00124007)
      • Phase II - Safety of and Immune Response to a DNA HIV Vaccine Followed By an Adenoviral Vector HIV Vaccine in Healthy Adults (NIAID: NCT00125970)
      • Phase I - Safety of and Immune Response to Two Experimental Preventive HIV Vaccines (EP HIV-1090 and EP-1043) Given Alone or in Combination in Healthy, HIV-1 Uninfected Adults (NIAID: NCT00141024)
      • Phase I - Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults (International AIDS Vaccine Initiative, Aaron Diamond AIDS Research Center, University of Rochester: NCT00252148)
  • CHAPTE R 5: Strategic Assessment of HIV/AIDS
    • Market Potential
    • Epidemiology
      • The ""Next Wave"" Countries
      • Nigeria
      • Ethiopia
      • Russia
      • India
      • China
    • Existing Epidemics-Africa
    • Technology
  • Appendix A: Glossary Appendix B: Companies Active in HIV/AIDS Therapeutics and Diagnostics
  • List of Exhibits
  • Chapter 1: Executive Summary
    • Table 1-1: Estimated Theoretical Global Market Potentials for HIV/AIDS Diagnostics and Therapeutics by Region (10 regions) 2005
    • Table 1-2: Estimated Realistic Global Market Potentials for HIV/AIDS Diagnostics and Therapeutics by Region (10 regions) 2005
    • Table 1-3: Global Epidemiology View of HIV/AIDS Incidence, Prevalence, Adult Prevalence, and Deaths by Region 2005
  • Chapter 2: HIV/AIDS: Nature and Epidemiology
    • Table 2-1: Global Summary of HIV/AIDS Populations Average and Range of Prevalance, Incidence, Deaths 2005
    • Table 2-2: Regional HIV/AIDS Statistic and Features: 2005
    • Table 2-3: Estimated Number of Cases of HIV/AIDS in the United States byYear of Diagnosis, Race/Ethnicity, and Transmission Category2001-2004
    • Table 2-4: Estimated Number of AIDS Cases in the United States by Age at Diagnosis, Race/Ethnicity, Transmission Category, and Region2000-2004
    • Table 2-5: Estimated Number of People Living with HIV/AIDS in the U.S. byAge at Diagnosis, Race/Ethnicity, and Transmission Category2001-2004
    • Table 2-6: Estimated Number of Persons Living with AIDS in the UnitedStates by Year, Race/Ethnicity, Transmission Category, andRegion 2000-2004
    • Table 2-7: HIV Diagnoses in Western Europe by Country (22 counties)Number of Diagnoses 2004 or 2003, Rate per Million, andCumulative Total
    • Table 2-8: Estimated Number of People Living with HIV in Western Europe by Country (26 countries) 2001 and 2003
    • Table 2-9: HIV Diagnoses in Central and Eastern Europe and in CentralAsia by Country: Number of Diagnoses 2004 or 2003, Rate perMillion, and Cumulative Total
    • Table 2-10: Estimated Number of People Living with HIV in Central andEastern Europe and Central Asia by Country (29 Countries)2001 and 2003
    • Table 2-11: Estimated Number of People Living with HIV in Sub-SaharanAfrica by Country (44 Countries) 2001 and 2003
    • Table 2-12: Estimated Number of People Living with HIV in Latin America by Country (20 Countries) 2001 and 2003
    • Table 2-13: Estimated Number of People Living with HIV in the Caribbean by Country (7 Countries) 2001 and 2003
    • Table 2-14: Estimated Number of People Living with HIV in India, China and South/Southeast Asia by Country (20 Countries Total)2001 and 2003
    • Table 2-15: Estimated Number of People Living with HIV in North Africaand the Middle East by Country (20 Countries) 2001 and 2003
  • Chapter 3: Screening and Diagnosis
    • Table 3-1: HIV Screening and Confirmatory Testing Products Approved forUse in the United States as of January 9, 2006
    • Table 3-2: Conditions Attributable to or Complicated by HIV
    • Table 3-3: AIDS: Indicator Conditions
  • Chapter 4: HIV/AIDS: Therapeutics
    • Table 4-1: Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Approved by the FDA for Use in HIV/AIDS Treatment (Brand Name, Generic Name, Manufacturer, Approval Date, Time to Approval)
    • Table 4-2: Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Approved by the FDA for Use in HIV/AIDS Treatment (Brand Name, Generic Name, Manufacturer, Approval Date, Time to Approval)
    • Table 4-3: Protease Inhibitors (PIs) Approved by the FDA for Use in HIV/AIDS Treatment (Brand Name, Generic Name, Manufacturer, ApprovalDate, Time to Approval)
    • Table 4-4: Generic Drugs Used in the Treatment of HIV Infection (GenericName, Manufacturer, Approval Date, Time to Approval)
    • Table 4-5: Drugs Approved by the FDA for Use in Pediatric HIV/AIDS Treatment (Generic Name, Manufacturer, Adult Approval Date, PediatricApproval Date)
    • Table 4-6: Drugs Approved by the FDA for Use in the Treatment of HIV/AIDS Complications (Brand Name, Generic Name[s], Use, Manufacturer,Approval Date)
  • Chapter 5: Strategic Assessment of HIV/AIDS
    • Figure 5-1: Theoretical Distribution of Global HIV/AIDS Diagnostics and Therapeutics Markets: 2005
    • Table 5-1: Estimated Theoretical Global Market Potentials for HIV/AIDS Diagnostics and Therapeutics by Region (10 regions) 2005
    • Table 5-2: Estimated Realistic Global Market Potentials for HIV/AIDSDiagnostics and Therapeutics by Region (10 regions) 2005
    • Figure 5-2: Realistic Distribution of Global HIV/AIDS Diagnostics andTherapeutics Markets: 2005
    • Figure 5-3: High and Low Estimates of Current and Future HIV/AIDS-Infected Adults in the ""Next-Wave"" Countries: 2002 and 2010
    • Table 5-3: High and Low Estimates of Current and Future HIV/AIDS-Infected Adults in the ""Next-Wave"" Countries 2002 and 2010
  • Other users found this report page using the following search terms: HIV AIDS diagnostics HIV assay HIV test hiv market india treatment kp1461 hivaids therapeutic therapeutics vaccine carraguard
  • If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.